Literature DB >> 6589432

Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.

H Shimada, J Chatten, W A Newton, N Sachs, A B Hamoudi, T Chiba, H B Marsden, K Misugi.   

Abstract

Histopathologic prognostic factors of 295 pretreatment tumors of a total 641 neuroblastomas and ganglioneuroblastomas were studied with the use of the following proposed tumor classification. The tumors were divided into 2 groups: stroma-poor (235 cases) and stroma-rich (60 cases) according to their organizational pattern (stromal development). The stroma-poor group was classified further into 2 subgroups: favorable stroma-poor (84% survival) and unfavorable stroma-poor (4.5% survival) according to the patient's age at diagnosis, degree of maturation, and nuclear pathology [mitosis-karyorrhexis index (MKI)] of the neuroblastic cells. The stroma-rich group was further classified into 3 subgroups: well differentiated (100% survival), intermixed (92% survival), and nodular (18% survival) on the basis of morphology of the immature element in the tumor tissue without regard to patient's age or quantitative maturation. Favorable stroma-poor and well-differentiated and intermixed stroma-rich groups seem to make good prognosis groups (87% survival), which show gradual progression along a maturational sequence according to the age of the patient. Unfavorable stroma-poor and nodular stroma-rich groups form poor prognosis groups (7% survival) and show morphological evidence of malignant or aggressive behavior, such as inappropriate immaturity for age, higher MKI, and gross nodule formation by immature neuroblasts.

Entities:  

Mesh:

Year:  1984        PMID: 6589432     DOI: 10.1093/jnci/73.2.405

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  154 in total

1.  Vitronectin expression in differentiating neuroblastic tumors: integrin alpha v beta 5 mediates vitronectin-dependent adhesion of retinoic-acid-differentiated neuroblastoma cells.

Authors:  C L Gladson; C Dennis; T C Rotolo; D R Kelly; J R Grammer
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Neuroblastoma with atypical metastases to cardiac and skeletal muscles: MRI features.

Authors:  Ricardo Faingold; Paul S Babyn; Shi-Joon Yoo; Anne I Dipchand; Sheila Weitzman
Journal:  Pediatr Radiol       Date:  2003-05-24

3.  Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.

Authors:  Octavio Burgues; Samuel Navarro; Rosa Noguera; Antonio Pellín; Amparo Ruiz; Victoria Castel; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

Review 4.  [Neuroblastoma].

Authors:  Victoria Castel; Adela Cañete; Rosa Noguera; Samuel Navarro; Silvestre Oltra
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

5.  Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

Authors:  David L Baker; Mary L Schmidt; Susan L Cohn; John M Maris; Wendy B London; Allen Buxton; Daniel Stram; Robert P Castleberry; Hiroyuki Shimada; Anthony Sandler; Robert C Shamberger; A Thomas Look; C Patrick Reynolds; Robert C Seeger; Katherine K Matthay
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

6.  Abdominal, retroperitoneal and sacrococcygeal tumours of the newborn and the very young infant. Report from the Kiel Paediatric Tumour Registry.

Authors:  D Harms; D Schmidt; I Leuschner
Journal:  Eur J Pediatr       Date:  1989-08       Impact factor: 3.183

7.  Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts.

Authors:  Shuqing Liu; Yufeng Tian; Alexandre Chlenski; Qiwei Yang; Peter Zage; Helen R Salwen; Susan E Crawford; Susan L Cohn
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

Authors:  John M Maris; George Hii; Craig A Gelfand; Shobha Varde; Peter S White; Eric Rappaport; Saul Surrey; Paolo Fortina
Journal:  Genome Res       Date:  2005-08       Impact factor: 9.043

9.  Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy.

Authors:  Edward F Attiyeh; Sharon J Diskin; Marc A Attiyeh; Yaël P Mossé; Cuiping Hou; Eric M Jackson; Cecilia Kim; Joseph Glessner; Hakon Hakonarson; Jaclyn A Biegel; John M Maris
Journal:  Genome Res       Date:  2009-01-13       Impact factor: 9.043

10.  Tumor stem cells: A new approach for tumor therapy (Review).

Authors:  Min Meng; Xin-Han Zhao; Qian Ning; Lei Hou; Guo-Hong Xin; Li-Feng Liu
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.